IDT Australia Limited reported sales results for the third quarter ended March 2023. For the quarter, revenue jumped 26% to $2.14 million over the previous quarter (and +168% over two quarters) due primarily to contracts won in IDT's Specialty Orals division. The demand outlook for Specialty Orals manufacturing is growing due to several factors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.095 AUD | 0.00% | -5.00% | -13.64% |
May. 06 | IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility | MT |
Apr. 16 | IDT Australia Signs Master Service Agreement with Sanofi | MT |
1st Jan change | Capi. | |
---|---|---|
-13.64% | 22.24M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.46% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- IDT Stock
- News IDT Australia Limited
- IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023